C4 Therapeutics, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-12-11

Reporting Person: Fisher Stewart (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-11	Common Stock	M	4743	$2.11	Acquired	90115	Direct
2020-12-11	Common Stock	M	9701	$3.71	Acquired	99816	Direct
2021-02-03	Common Stock	M	2371	$2.11	Acquired	102187	Direct
2021-02-03	Common Stock	M	5929	$3.71	Acquired	108116	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-11	Stock Option (Right to Buy)	$2.11	M	4743	Disposed	2026-07-12	Common Stock (4743)	Direct
2020-12-11	Stock Option (Right to Buy)	$3.71	M	9701	Disposed	2028-04-23	Common Stock (9701)	Direct
2021-02-03	Stock Option (Right to Buy)	$2.11	M	2371	Disposed	2026-07-12	Common Stock (2371)	Direct
2021-02-03	Stock Option (Right to Buy)	$3.71	M	5929	Disposed	2028-04-23	Common Stock (5929)	Direct

Footnotes

F1: The Form 3 filed on October 1, 2020 included an incorrect exercise price in Table II, Column 2 ($3.72).

F2: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on May 2, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.

F3: Represents underlying unexercised stock options that were granted on April 24, 2018. The terms of the original grant provide that 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.